Search
Search
Farhad Hafezi, MD, PhD
Show Description +
Farhad Hafezi, MD, PhD, comments on the effect of corneal crosslinking (CXL) in children and adolescents with keratoconus. Dr. Hafezi describes different discrepancies between study outcomes regarding the longevity of CXL's beneficial effects. He also shares findings from a meta-analysis showing that 22% of young patients with keratoconus had reactivation of the disease 5 years after CXL.
Posted: 10/08/2017
Farhad Hafezi, MD, PhD
Farhad Hafezi, MD, PhD, comments on the effect of corneal crosslinking (CXL) in children and adolescents with keratoconus. Dr. Hafezi describes different discrepancies between study outcomes regarding the longevity of CXL's beneficial effects. He also shares findings from a meta-analysis showing that 22% of young patients with keratoconus had reactivation of the disease 5 years after CXL.
Posted: 10/08/2017
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ESCRS: 2017.
Please log in to leave a comment.
Comments
Just Now
polly campbell
7 years ago
are these figures the same for ectasia?